CVS Caremark 4Q profit rises, 2012 outlook climbs

Associated Press
A sign at a CVS Pharmacy welcomes Express Script Customers on its sign at a store in Indianapolis, Wednesday, Feb. 8, 2012. CVS Caremark says its fourth-quarter earnings climbed nearly 4 percent, as the drugstore operator's pharmacy services revenue swelled because of a long-term contract and new business. (AP Photo/Michael Conroy)
.

View gallery

A sign at a CVS Pharmacy welcomes Express Script Customers on its sign at a store in Indianapolis, Wednesday, …

Drugstore chain Walgreen's loss of a big client is turning into rival CVS Caremark's gain so far this year.

A contract squabble between Walgreen Co. and pharmacy benefits manager Express Scripts Inc. has driven more customers to CVS pharmacies, prompting that company to raise its 2012 earnings forecast by 3 cents per share.

CVS Caremark Corp. said in December it would gain business because of the dispute, but CEO Larry Merlo told analysts Wednesday the company is seeing more prescription transfers than it expected. He said CVS Caremark's chances of retaining those customers improve the longer the impasse continues, especially once people refill their prescriptions a few times and get to know the pharmacist and store staff.

"As I have said in the past, we know that that pharmacy customer is the hardest person to lose, but once you lose them, it's the hardest person to get back," he said.

Walgreen stopped filling prescriptions for Express Scripts at the end of 2011, when a contract between the two companies ran out and they were unable to negotiate a new one. Pharmacy benefits managers, or PBMs, run prescription drug plans and use large purchasing power to negotiate lower drug prices. They make their money by reducing costs for health plan sponsors and members.

Walgreen said Friday that January revenue from stores open at least a year fell 4.6 percent, as the Express Scripts split and a weak flu season hurt business.

CVS Caremark, based in Woonsocket, R.I., runs the second-largest chain of drugstores in the U.S., after Walgreen, and its Caremark unit is one of the largest PBMs.

Overall, CVS Caremark's earnings from the fourth quarter of 2011 climbed nearly 4 percent. The company earned $1.06 billion, or 81 cents per share, in the three months that ended Dec. 31. That compares with $1.03 billion, or 75 cents per share, in the final quarter of 2010.

Adjusted earnings were 89 cents per share, in line with the average analyst forecast, according to FactSet.

Revenue rose 15 percent to $28.32 billion, above the $28.09 billion analysts expected.

Revenue from the company's PBM side jumped 32 percent to $15.9 billion in the quarter because of the addition of a long-term contract with health insurer Aetna Inc. and new sales that came from the acquisition of insurer Universal American Corp.'s Medicare prescription drug business.

Drugstore revenue increased 4 percent, as pharmacy revenue at stores open at least a year climbed 3.6 percent. Revenue at stores open at least a year is a key indicator of a retailer's health, because it excludes the impact of recently opened or closed stores.

Non-pharmacy, or front-of-the-store, sales rose only slightly. CVS said Christmas sales came in lower than it had planned, and a weak flu season also affected those results.

For the full year, the company earned $3.46 billion, or $2.59 per share, on $107.1 billion in revenue. Analysts expect, on average, earnings of $3.26 per share.

CVS Caremark now forecasts 2012 adjusted earnings of $3.18 to $3.28 per share. The company said this new forecast doesn't reflect a benefit from the Walgreen-Express Scripts dispute beyond the first quarter.

BMO Capital Markets analyst Dave Shove noted that CVS Caremark's retail pharmacies gained market share in the fourth quarter. He said in a research note he suspects the Walgreen-Express Scripts dispute will help carry that momentum into the first half of 2012.

CVS Caremark opened 24 drugstores in the fourth quarter and closed one. It operated 7,327 as of Dec. 31.

Company shares climbed 49 cents to close at $43.57 Wednesday, outpacing a slight gain by the Standard & Poor's 500 index.

View Comments (0)